@article{JGO645,
author = {Yasuhito Hisatsune and Hiroshi Nakano and Yoshitaka Mihara and Naotaka Tobe and Kazuyoshi Ishibashi and Tsukasa Shimamura and Kei-ichi Tanaka and Yoshio Aida and Takehito Otsubo},
title = {A patient who showed a pathologically complete response after undergoing treatment with XELOX plus bevacizumab for synchronous liver metastasis of grade H2 from sigmoid colon cancer},
journal = {Journal of Gastrointestinal Oncology},
volume = {4},
number = {2},
year = {2012},
keywords = {},
abstract = {We herein report the case of a patient who showed a pathological complete response after undergoing chemotherapy with capecitabine, oxaliplatin and bevacizumab. The patient presented with synchronous solitary liver metastasis from sigmoid colon cancer. The maximum diameter of the liver deposit was 5.7 cm and the grade of the liver metastasis was H2 according to the Japanese classification. Deferred hepatectomy after sigmoidectomy was performed, followed by the administration of neoadjuvant chemotherapy. After undergoing sigmoidectomy, the patient received 1,000 mg/m2 of capecitabine and 130 mg/m2 of oxaliplatin without bevacizumab as the first cycle of chemotherapy followed by eight cycles of chemotherapy with bevacizumab (7.5 mg/kg) every three weeks. The liver deposit was reduced to 2.2 cm in diameter and the patient showed a partial response to chemotherapy. The patient then underwent metastasectomy of segment 8 of the liver instead of the central hepatectomy that was possibly needed before chemotherapy. Histopathologically, the tumor consisted of fibrous tissue, and no cancer cells were detected in the resected specimen. A pathological complete response in a patient with H2 liver metastasis is considered rare and suggests that capecitabine, oxaliplatin and bevacizumab are efficacious as neoadjuvant chemotherapy.},
issn = {2219-679X}, url = {https://jgo.amegroups.org/article/view/645}
}